摘要
拓扑异构酶Ⅱα(TOP2α)是控制DNA拓扑状态和细胞增殖的一类酶蛋白。它可能成为一种新型前列腺癌(PCa)的标记物,同时可以较好地评估PCa患者的预后。将有助于预测PCa预后、评估疗效及降低医疗成本。本文将对该标记物的特点及临床应用作一综述。
TopoisomeraseⅡα,a zymoprotein,controls DNA topological structure and cell cycle progression.This enzyme may be a tumor marker of cell proliferation in prostate cancer.It evaluates the prognosis of prostate cancer very well,so it is helpful for us to prognosticate prostate cancer,evaluate the treatment and reduce the medical cost.This article reviews the characteristic of the marker and its clinical application.
作者
牛吉瑞
纪志刚
NIU Jirui;JI Zhigang(Department of Urology,Heilongjiang Provincial Hospital,Harbin,150036,China;Department of Urology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College)
出处
《临床泌尿外科杂志》
2019年第2期157-160,共4页
Journal of Clinical Urology
基金
黑龙江省卫生计生委科研课题(编号2017-481)
